Biomedical Development Corporation
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1984-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.biodevcorp.com/
Informational App Development for mHealth for Patient Self-Management of Opioid Use Disorder
- Conditions
- Opioid-Related Disorders
- Interventions
- Device: KIOS Informational App
- First Posted Date
- 2023-05-15
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- Biomedical Development Corporation
- Target Recruit Count
- 25
- Registration Number
- NCT05859035
- Locations
- 🇺🇸
UT Health San Antonio, San Antonio, Texas, United States
mHealth for Patient Self-Management of Opioid Use Disorder
- Conditions
- Opioid-use Disorder
- Interventions
- Other: KIOS OUD
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Biomedical Development Corporation
- Target Recruit Count
- 19
- Registration Number
- NCT03633929
- Locations
- 🇺🇸
Community Medical Services, San Antonio, Texas, United States
🇺🇸Biomedical Development Corporation, San Antonio, Texas, United States
Efficacy of Iocide Oral Rinse Against Gingival Inflammation
- Conditions
- GingivitisInvestigation of Biological Markers of Inflammation
- Interventions
- Drug: Iocide Oral RinseDrug: Placebo
- First Posted Date
- 2013-02-01
- Last Posted Date
- 2013-08-14
- Lead Sponsor
- Biomedical Development Corporation
- Target Recruit Count
- 76
- Registration Number
- NCT01782170
- Locations
- 🇺🇸
University of Kentucky, Center for Oral Health Research, College of Dentistry, Lexington, Kentucky, United States
Relationship Between Vestibular Function and Topographic Memory
- Conditions
- Normal Elderly Population
- First Posted Date
- 2013-01-31
- Last Posted Date
- 2013-02-01
- Lead Sponsor
- Biomedical Development Corporation
- Target Recruit Count
- 50
- Registration Number
- NCT01780896
- Locations
- 🇺🇸
Ears of Texas, PA, San Antonio, Texas, United States
🇺🇸Michael Roman, PhD, LSSP, San Antonio, Texas, United States
Dose-Response Study of Iocide Oral Rinse
- Conditions
- Gingivitis
- Interventions
- Drug: Iocide Oral RinseDrug: Placebo
- First Posted Date
- 2010-04-14
- Last Posted Date
- 2013-01-29
- Lead Sponsor
- Biomedical Development Corporation
- Target Recruit Count
- 97
- Registration Number
- NCT01103102
- Locations
- 🇺🇸
University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
Treatment and/or Prevention of Urinary Tract Infections
- Conditions
- CystitisUrinary Tract Infections
- Interventions
- Drug: Frio Mouth Rinse
- First Posted Date
- 2008-12-03
- Last Posted Date
- 2010-03-08
- Lead Sponsor
- Biomedical Development Corporation
- Target Recruit Count
- 3
- Registration Number
- NCT00801021
- Locations
- 🇺🇸
Ben Taub General Hospital, Houston, Texas, United States
Exploratory Study of Iocide Oral Rinse in a Diabetic Population
- Conditions
- Diabetes Type 2Periodontitis
- Interventions
- Drug: Frio Mouth RinseDrug: Frio Mouth Rinse Placebo
- First Posted Date
- 2008-12-03
- Last Posted Date
- 2012-02-02
- Lead Sponsor
- Biomedical Development Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT00801164
- Locations
- 🇺🇸
The University of Texas Health Science Center at San Antonio, Dental School, San Antonio, Texas, United States
Novel Topical Treatment of Hand Dermatitis (Eczema)
- Conditions
- Eczema, ContactContact Dermatitis
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2010-03-08
- Lead Sponsor
- Biomedical Development Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT00614289
- Locations
- 🇺🇸
UTHSC Houston, Dermatology Clincial Research Center, Houston, Texas, United States
Novel Rinse to Treat in Oral Candidiasis in Cancer Patients
- Conditions
- Candidiasis, OralThrushCandidiasis
- First Posted Date
- 2008-02-12
- Last Posted Date
- 2010-03-08
- Lead Sponsor
- Biomedical Development Corporation
- Target Recruit Count
- 23
- Registration Number
- NCT00612963
- Locations
- 🇺🇸
University of Missouri at Kansas City, School of Dentistry, Kansas City, Missouri, United States
🇺🇸Cancer Therapy and Researh Center, San Antonio, Texas, United States
New Topical Treatment for Continued Pain After Shingles
- Conditions
- Postherpetic Neuralgia
- Interventions
- Drug: Epikeia coatings with aspirinDrug: Epikeia coatings with lidocaineOther: Epikeia coatings alone
- First Posted Date
- 2007-12-04
- Last Posted Date
- 2011-08-31
- Lead Sponsor
- Biomedical Development Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT00566904
- Locations
- 🇺🇸
Dermatology Clincial Reseach Center, Houston, Texas, United States